Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of hematology"
DOI: 10.1002/ajh.26954
Abstract: It remains unclear if immune checkpoint inhibitor (ICI) therapy is associated with higher rate of venous thromboembolism (VTE) compared with cytotoxic chemotherapy (chemo) in patients with comparable cancer type, staging, and comorbidities. Using the national… read more here.
Keywords: first line; ici chemo; cancer; chemo ... See more keywords
Abstract CT086: Pneumonitis incidence in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy in clinical trials and real-world data
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct086
Abstract: Background: Pneumonitis (Pn) is a potentially life-threatening adverse event of some anticancer drugs. We compared treatment associated pneumonitis (TAP) related to immune checkpoint inhibitors (ICI) or chemotherapies (chemo) in advanced non-small cell lung cancer (aNSCLC)… read more here.
Keywords: incidence; cancer; ici chemo; pneumonitis ... See more keywords
Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Translational lung cancer research"
DOI: 10.21037/tlcr-21-815
Abstract: Background The baseline tumor size (BTS) is a prognostic factor for patients with non-small cell lung cancer (NSCLC) who received immune checkpoint inhibitor monotherapy (ICI-mono). However, this relationship is not yet known in patients treated… read more here.
Keywords: treated ici; max bts; ici mono; ici chemo ... See more keywords